LDE225
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumor Cancers
Conditions
Advanced Solid Tumor Cancers, Medulloblastoma, Basal Cell Carcinoma
Trial Timeline
Oct 1, 2010 → Oct 1, 2013
NCT ID
NCT01208831About LDE225
LDE225 is a phase 1 stage product being developed by Novartis for Advanced Solid Tumor Cancers. The current trial status is completed. This product is registered under clinical trial identifier NCT01208831. Target conditions include Advanced Solid Tumor Cancers, Medulloblastoma, Basal Cell Carcinoma.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumor Cancers were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02195973 | Phase 1 | Completed |
| NCT02151864 | Phase 1 | Completed |
| NCT02086513 | Phase 1 | Terminated |
| NCT02002689 | Phase 2 | Terminated |
| NCT01826214 | Phase 2 | Completed |
| NCT01764776 | Phase 1 | Completed |
| NCT01529450 | Pre-clinical | Completed |
| NCT01327053 | Phase 2 | Completed |
| NCT01125800 | Phase 1/2 | Completed |
| NCT01208831 | Phase 1 | Completed |
| NCT00880308 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced Solid Tumor Cancers